Bourla said the experts were helping Pfizer "make better and more sound decisions," and the company could start a late-stage study of its drug, danuglipron, in the second half of this year.

Pfizer said its patent on the drug is valid until 2027. Chen Bo, CR Pharmaceutical’s chief scientist, said the company is seeking to repurpose the drug after findings from a preclinical research ...